亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

多西紫杉醇 医学 前列腺癌 封锁 肿瘤科 内科学 化疗 前列腺 血液学 雄激素 癌症 泌尿科 受体 激素
作者
Mark Thalgott,Thomas Horn,Matthias Heck,Tobias Maurer,Matthias Eiber,Margitta Retz,Michael Autenrieth,Kathleen Herkommer,Bernd J. Krause,Jürgen E. Gschwend,Uwe Treiber,Hubert Kübler
出处
期刊:Journal of Hematology & Oncology [BioMed Central]
卷期号:7 (1) 被引量:38
标识
DOI:10.1186/1756-8722-7-20
摘要

Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complete androgen blockade (CAB) in locally advanced and high-risk prostate cancer patients (LAPC) undergoing RP. Patients (n = 30) were selected by Kattans’ preoperative score and received trimestral buserelin 9,45 mg, bicalutamide 50 mg/day and 3 cycles docetaxel (75 mg/m2) followed by RP. Primary endpoints were biochemical (PSA) and local downstaging. Secondary endpoints included toxicity and operability assessments, pathological complete response (pCR), time to PSA progression, 5-year biochemical recurrence free survival (bRFS) and overall survival (OS). Median baseline PSA was 25.8 ng/ml (2.1–293), and the predicted probability of 5-year bRFS was 10% (0–55). NCHT induced PSA-reduction was 97.3% (81.3-99.9%; p < 0.001) and post-RP 96.7% of patients were therapy responders, with undetectable PSA-values. Post- vs. pretreatment MRI indicated a median tumor volume reduction of 46.4% (−31.3-82.8; p < 0.001). A pathological downstaging was observed in 48.3%. Severe hematologic toxicities (≥CTC3) were frequent with 53.8% leucopenia, 90% neutropenia and 13.3% febrile neutropenia. RP was performed in all patients. While resectability was hindered in 26.7%, continence was achieved in 96.7%. Pathologic analyses revealed no pCR. Lymph node- and extracapsular involvement was observed in 36.7% and 56.7% with 33.3% positive surgical margins. After a median of 48.6 (19.9-87.8) months, 55.2% of therapy responders experienced PSA-recurrence. The estimated median time to PSA-progression was 38.6 months (95%CI 30.9-46.4) and 85.3 months (95%CI 39.3–131.3) for OS. The 5-year bRFS was improved to 40%, but limiting for interpretation adjuvant treatment was individualized. NCHT is feasible despite high hematotoxicity, with excellent functional results. Significant downstaging was observed without pCR. NCHT seems to improve the cohort adjusted 5-year bRFS, but clinical value needs further investigation in randomized trials.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李诗语发布了新的文献求助10
1秒前
粗心的丹萱完成签到,获得积分10
3秒前
13秒前
14秒前
共享精神的应助被叶素绿采纳,获得10
20秒前
6666发布了新的文献求助10
21秒前
科研通AI6.4的应助被豆花鱼采纳,获得10
24秒前
www发布了新的文献求助10
26秒前
小蘑菇的应助被www采纳,获得10
34秒前
清爽晓博发布了新的文献求助10
36秒前
可久斯基完成签到 ,获得积分10
41秒前
深情豁完成签到,获得积分10
51秒前
54秒前
54秒前
叶素绿发布了新的文献求助10
58秒前
水滇发布了新的文献求助10
1分钟前
失眠的白云完成签到,获得积分10
1分钟前
科研通AI6.3的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.4的应助被纯情的阁采纳,获得100
1分钟前
Ava的应助被纯情的阁采纳,获得10
1分钟前
Lucas的应助被纯情的阁采纳,获得50
1分钟前
科研通AI6.3的应助被纯情的阁采纳,获得20
1分钟前
1分钟前
Owen的应助被科研通管家采纳,获得10
1分钟前
英俊的铭的应助被科研通管家采纳,获得10
1分钟前
菌菌的应助被科研通管家采纳,获得10
1分钟前
大个的应助被科研通管家采纳,获得10
1分钟前
大连理工官方完成签到 ,获得积分10
1分钟前
美好的初翠完成签到,获得积分10
1分钟前
水滇完成签到,获得积分10
1分钟前
1分钟前
1分钟前
www发布了新的文献求助10
1分钟前
ding的应助被纯情的阁采纳,获得10
1分钟前
Ricky小强完成签到,获得积分10
1分钟前
小小昌完成签到,获得积分20
1分钟前
短短急个球完成签到,获得积分0
1分钟前
1分钟前
烂漫亦巧完成签到,获得积分10
2分钟前
曾经凌萱发布了新的文献求助10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179836
求助须知:如何正确求助?哪些是违规求助? 9570035
关于积分的说明 21808122
捐赠科研通 7775481
什么是DOI,文献DOI怎么找? 3433157
关于科研通互助平台的介绍 2557262
邀请新用户注册赠送积分活动 2478832